Docs rate top specialty reps in survey

Share this article:

Physicians were asked to rank the companies that have the best general sales reps, specialty sales reps, and medical science liaisons as part of “Specialty Reps 2007: An Influential Force,” a recent Verispan survey of 4,000 physicians from across 24 different specialties.

Here's a look at what docs from each specialty had to say about the specialty sales reps that serve them.

Cardiologists rated Pfizer, Merck and Novartis first, second and third respectively as the companies with the best specialty sales forces. Gastroenterologists rated AstraZeneca, TAP and Abbott as the top three sales forces for specialty reps. Neurologists/neurosurgeons ranked Pfizer, GlaxoSmithKline, UCB and Novartis as having the best specialty reps. OB/GYNs ranked Wyeth, Ortho-McNeil and Bayer first, second and third, respectively in terms of best specialty reps. Oncologists rated Genentech, Amgen and Novartis as having the best specialty reps.

Ophthalmologists ranked Alcon, Allergan and Pfizer as the leasing sales forces in terms of specialty reps.

Pediatricians ranked Merck, GlaxoSmithKline and Shire as the top three sales forces for specialty reps. Psychiatrists ranked Eli Lilly, Janssen and Pfizer as having the leading specialty sales reps. Urologists rated Pfizer, Sanofi-Aventis and GlaxoSmithKline first, second and third, in terms of best specialty representatives.  
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...